NLRP3 and Alzheimer disease: Despite the aforementioned limitations, the A2A receptor and the NLRP3 inflammasome are attractive therapeutic targets to treat ailments, including neurodegenerative diseases, and the extensive work in research treatments utilizing this strategy, particularly for AD, look promising.